Expression And Significance Of Tumor Marker, Immunohistochemical Biomarkers In Gastric Carcinoma

1. ObjectiveThis study aims to describe the characteristics of 212 patients of Gastric carcinoma admitted during Jan 2012 to Jun 2014. We analyzed the tumor marker (CEA、CA72-4、CA19-9、CA125) and immunohistochemical biomarkers (Her-2、 Ki67、EGFR、p53、TOP2a) in the patients, then to explore the difference of tumor marker and immunohistochemical biomarker among the different stages of gastric cancer,different pathological types, and to evaluate the significance of combined detection in diagnosis of gastric cancer. We explore the relationship between the tumor marker and immunohistochemical biomarkers, and to discuss the early diagnosis as well as the method to prevent misdiagnosis, and to evaluate the effect of clinical treatment.2. MethodsIn this study, we retrospectively collected patients of concurrent gastric cancer during Jan 2012 to Jun 2014. We collected the tumor marker and immunohistochemical biomarkers and other clinical data of 212 patients. We described the degree of differentiation of gastric cancer, TNM stage, stomach invasion, tumor size, histological type and lymph node metastasis of 212 patients. All data were processed by SPSS 18.0 software. We used chi-square test to test the rate of tumor marker and immunohistochemical biomarkers. We explore the diagnosis significant of this biomarkers, and thus provide the basis for disease monitoring and prognosis of gastric cancer patients.3. Results(1) The expressions of the serum CA125 levels were significantly different between the Gastric Ⅰ stage, Ⅱ stage,Ⅲstage and Ⅳ stage patients. The serum CEA levels and CA125 levels in Ⅳstage patients were higher than II stage and Ⅲstage patients. These results suggest that CEA and CA125 levels expression was associated with clinical stage of gastric cancer patients.(2) Combined detection the serum CEA, CA125, CA199 and CA724 levels was significantly better than the single test compared with the individual testing the biomarker of cancer Ⅱ stage,Ⅲstage and IV stage patients.(3) The serum CEA, CA125, CA199 and CA724 levels were not statistically significant among the gender and different age group. Serum CEA, CA199,CA724 levels were significant different between the tumor≤ 5cm and tumor> 5cm group. Serum CA199 and CA724 levels were significant different among the stomach invasion groups, and serum CEA and CA125 levels were no significant different among the stomach invasion groups. The serum CEA, CA125 and CA724 levels in lymph node metastasis was significantly higher than that of lymph node not metastasis.(4) The positive rate of Her-2, TOP2a, Ki67, p53 and EGFR were significant different among the gender and different age group. The level of Her-2 in lymph node metastasis was significantly higher than that of lymph node not metastasis.4. Conclusions(1) Serum tumor markers CEA and CA125 expression were associated with the clinical tumor stage, which can be used to diagnose the gastric cancer patients. Combined detection the serum tumor marker level was significantly better than the single test compared with the individual testing the biomarker of patients.(2) The serum CEA, CA125, CA199 and CA724 levels were significantly different among the different tumor size, stomach invasion and different pathological types group.(3) The levels of Her-2 were associated with tumor size and clinical stage of gastric cancer patients.